Annual Accounts Receivable
$0.00
-$1.70 M-100.00%
31 December 2023
Summary:
Inovio Pharmaceuticals annual accounts receivable is currently $0.00, with the most recent change of -$1.70 million (-100.00%) on 31 December 2023. During the last 3 years, it has fallen by -$18.56 million (-100.00%). INO annual accounts receivable is now -100.00% below its all-time high of $18.56 million, reached on 31 December 2020.INO Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
N/A
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly accounts receivable is not available.INO Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -100.0% | - |
| 3 y3 years | -100.0% | - |
| 5 y5 years | -100.0% | - |
INO Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -100.0% | |||
| 5 y | 5 years | -100.0% | |||
| alltime | all time | -100.0% |
Inovio Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2023 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2023 | - | $0.00(-100.0%) |
| June 2023 | - | $5900.00(-92.0%) |
| Mar 2023 | - | $73.30 K(-95.7%) |
| Dec 2022 | $1.70 M(-68.9%) | $1.70 M(-30.3%) |
| Sept 2022 | - | $2.44 M(-45.5%) |
| June 2022 | - | $4.48 M(+12.0%) |
| Mar 2022 | - | $4.00 M(-26.8%) |
| Dec 2021 | $5.47 M(-70.5%) | $5.47 M(+14.6%) |
| Sept 2021 | - | $4.77 M(-63.7%) |
| June 2021 | - | $13.13 M(+32.4%) |
| Mar 2021 | - | $9.91 M(-46.6%) |
| Dec 2020 | $18.56 M(+2551.0%) | $18.56 M(+141.3%) |
| Sept 2020 | - | $7.69 M(+119.0%) |
| June 2020 | - | $3.51 M(+447.6%) |
| Mar 2020 | - | $641.60 K(-8.4%) |
| Dec 2019 | $700.10 K(-78.9%) | $700.10 K(-9.8%) |
| Sept 2019 | - | $776.30 K(+496.2%) |
| June 2019 | - | $130.20 K(-95.3%) |
| Mar 2019 | - | $2.78 M(-16.1%) |
| Dec 2018 | $3.32 M(-44.8%) | $3.32 M(+17.1%) |
| Sept 2018 | - | $2.83 M(+65.3%) |
| June 2018 | - | $1.71 M(-66.7%) |
| Mar 2018 | - | $5.15 M(-14.2%) |
| Dec 2017 | $6.00 M(-62.1%) | $6.00 M(-3.8%) |
| Sept 2017 | - | $6.24 M(-17.1%) |
| June 2017 | - | $7.52 M(-23.7%) |
| Mar 2017 | - | $9.86 M(-37.6%) |
| Dec 2016 | $15.82 M(+116.7%) | $15.82 M(-9.4%) |
| Sept 2016 | - | $17.46 M(+68.4%) |
| June 2016 | - | $10.37 M(-7.1%) |
| Mar 2016 | - | $11.15 M(+52.8%) |
| Dec 2015 | $7.30 M(+160.3%) | $7.30 M(-33.4%) |
| Sept 2015 | - | $10.97 M(+95.5%) |
| June 2015 | - | $5.61 M(+70.0%) |
| Mar 2015 | - | $3.30 M(+17.7%) |
| Dec 2014 | $2.80 M(-15.1%) | $2.80 M(+72.9%) |
| Sept 2014 | - | $1.62 M(-43.6%) |
| June 2014 | - | $2.88 M(+6.6%) |
| Mar 2014 | - | $2.70 M(-18.2%) |
| Dec 2013 | $3.30 M(+297.6%) | $3.30 M(-68.8%) |
| Sept 2013 | - | $10.57 M(+1857.1%) |
| June 2013 | - | $540.30 K(-47.5%) |
| Mar 2013 | - | $1.03 M(+23.9%) |
| Dec 2012 | $830.40 K | $830.40 K(+72.5%) |
| Sept 2012 | - | $481.40 K(+11.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2012 | - | $432.10 K(-50.7%) |
| Mar 2012 | - | $876.70 K(+87.4%) |
| Dec 2011 | $467.90 K(+345.6%) | $467.90 K(+2.8%) |
| Sept 2011 | - | $455.20 K(+30.9%) |
| June 2011 | - | $347.80 K(+104.9%) |
| Mar 2011 | - | $169.70 K(+61.6%) |
| Dec 2010 | $105.00 K(-67.0%) | $105.00 K(-51.3%) |
| Sept 2010 | - | $215.70 K(-90.1%) |
| June 2010 | - | $2.19 M(-35.7%) |
| Mar 2010 | - | $3.41 M(+970.5%) |
| Dec 2009 | $318.10 K(-52.6%) | $318.10 K(-76.2%) |
| Sept 2009 | - | $1.34 M(-5.7%) |
| June 2009 | - | $1.42 M(+483.8%) |
| Mar 2009 | - | $243.20 K(-63.8%) |
| Dec 2008 | $671.20 K(-41.1%) | $671.20 K(-9.3%) |
| Sept 2008 | - | $740.40 K(+32.0%) |
| June 2008 | - | $560.80 K(+17.6%) |
| Mar 2008 | - | $476.80 K(-58.2%) |
| Dec 2007 | $1.14 M(+249.6%) | $1.14 M(+289.6%) |
| Sept 2007 | - | $292.60 K(-19.3%) |
| June 2007 | - | $362.50 K(+45.8%) |
| Mar 2007 | - | $248.70 K(-23.7%) |
| Dec 2006 | $326.10 K(+14.7%) | $326.10 K(+7.2%) |
| Sept 2006 | - | $304.10 K(-21.1%) |
| June 2006 | - | $385.20 K(-10.7%) |
| Mar 2006 | - | $431.50 K(+51.8%) |
| Dec 2005 | $284.20 K(-33.0%) | $284.20 K(+0.7%) |
| Sept 2005 | - | $282.20 K(-88.8%) |
| June 2005 | - | $2.52 M(+447.0%) |
| Mar 2005 | - | $461.50 K(+8.8%) |
| Dec 2004 | $424.20 K(+142.4%) | $424.20 K(+20.8%) |
| Sept 2004 | - | $351.20 K(+4777.8%) |
| Mar 2004 | - | $7200.00(-95.9%) |
| Dec 2003 | $175.00 K(+131.5%) | $175.00 K(+5368.8%) |
| June 2003 | - | $3200.00(-98.1%) |
| Mar 2003 | - | $171.40 K(+126.7%) |
| Dec 2002 | $75.60 K(-92.0%) | $75.60 K(+749.4%) |
| Sept 2002 | - | $8900.00(-83.8%) |
| June 2002 | - | $54.90 K(-90.9%) |
| Mar 2002 | - | $606.30 K(-28.6%) |
| Dec 2001 | $940.30 K(+4.1%) | - |
| Sept 2001 | - | $849.20 K(+7.2%) |
| June 2001 | - | $791.80 K(-12.4%) |
| Mar 2001 | - | $903.50 K(-19.4%) |
| Mar 2001 | $903.50 K(-19.4%) | - |
| Mar 2000 | $1.12 M(+40.1%) | $1.12 M(+40.1%) |
| Mar 1999 | $800.00 K | $800.00 K |
FAQ
- What is Inovio Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual accounts receivable year-on-year change?
- What is the all time high quarterly accounts receivable for Inovio Pharmaceuticals?
What is Inovio Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of INO is $0.00
What is the all time high annual accounts receivable for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual accounts receivable is $18.56 M
What is Inovio Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, INO annual accounts receivable has changed by -$1.70 M (-100.00%)
What is the all time high quarterly accounts receivable for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly accounts receivable is $18.56 M